These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17277852)

  • 21. Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.
    Oh CK; Kim SJ; Kim JH; Lee JH
    J Korean Med Sci; 2012 Apr; 27(4):337-42. PubMed ID: 22468094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG; Davies EA; Mourad G; Oppenheimer F; Molina MG; Rostaing L; Wilkinson AH; Mulloy LL; Bourbigot BJ; Prestele H; Korn A; Girault D;
    Transplantation; 2003 Jan; 75(1):37-43. PubMed ID: 12544868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs.
    Delucchi A; Valenzuela M; Ferrario M; Lillo AM; Guerrero JL; Rodriguez E; Cano F; Cavada G; Godoy J; Rodriguez J; Gonzalez CG; Buckel E; Contreras L
    Pediatr Transplant; 2007 Nov; 11(7):743-8. PubMed ID: 17910651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O
    Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
    Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation.
    De Paolis P; Favarò A; Piola A; Martini F; Cristiana G; Agrati C; Iappelli M; Di Giulio S
    Transplant Proc; 2011 May; 43(4):1013-6. PubMed ID: 21620039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM; Taylor RM; Verma A; Parke A; Baker AJ; Hadzic D; Muiesan P; Rela M; Heaton ND; Mieli-Vergani G; Dhawan A
    Transplantation; 2003 Mar; 75(6):796-9. PubMed ID: 12660504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
    Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
    Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.
    Guba M; Rentsch M; Wimmer CD; Uemueksuez A; Illner WD; Schönermarck U; Land WG; Jauch KW; Arbogast H
    Transpl Int; 2008 Jul; 21(7):637-45. PubMed ID: 18282242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
    Mendez R; Gonwa T; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2005 Aug; 80(3):303-9. PubMed ID: 16082323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
    Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
    Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.